Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations Read more
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy. Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety And Efficacy Of Pf-07284890 (Arry-461) In Participants With Braf V600-Mutant Solid Tumors With And Without Brain Involvement Read more
Phase II Trial Of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy Of Checkpoint Therapy Resistant Solid Tumors Read more
A Phase 1/2 Study Of Tpx-0131, A Novel Oral Alk Tyrosine Kinase Inhibitor In Subjects With Alk+ Advanced Or Metastatic Nsclc Read more
A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Read more
An Open-Label, Multicenter Phase I Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics And Maximum Tolerated Dose Of VIP152 (BAY 1251152) In Subjects With Advanced Cancer Read more
